Lead Product(s) : Human C1 Esterase Inhibitor
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The latest FDA approval was based on results from two CSL Behring-sponsored COMPACT trials. In the COMPACT pivotal study, HAEGARDA, at the FDA approved dose of 60 IU/kg, reduced the number of HAE attacks by a median of 95% relative to placebo.
Product Name : Haegarda
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Human C1 Esterase Inhibitor
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
